What is the recommended dose of Rebamipide (Rebamipide) for treating gastritis and gastric ulcers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dose of Rebamipide for Gastritis and Gastric Ulcers

The standard recommended dose of rebamipide for treating gastritis and gastric ulcers is 100 mg three times daily.

Dosing Regimen

  • Rebamipide is typically administered at a dose of 100 mg three times daily for the treatment of gastric ulcers and gastritis 1
  • The standard treatment duration for gastric ulcers is 8 weeks, which has been shown to be effective for promoting ulcer healing 1
  • Rebamipide reaches its maximal concentration in gastric mucosa within 30-60 minutes after oral administration, and remains elevated for approximately 120 minutes 2
  • The mean mucosal concentration of rebamipide between 30-120 minutes after ingestion is 60.0 ± 109.8 μg/g of tissue, which is sufficient for its therapeutic effect 2

Formulations and Administration

  • Rebamipide is available in both tablet (100 mg) and granule (20%/0.5g) formulations 3
  • The granule formulation may be more appropriate for patients with difficulty swallowing tablets 3
  • Both formulations are bioequivalent, with similar pharmacokinetic profiles 3
  • The maximum plasma concentration (Cmax) is reached approximately 2.4-2.5 hours after administration 3

Clinical Efficacy

  • Rebamipide has demonstrated effectiveness in healing gastric ulcers, particularly those caused by NSAIDs 4
  • The drug works by multiple mechanisms:
    • Stimulation of prostaglandin and mucus glycoprotein synthesis
    • Inhibition of reactive oxygen species
    • Reduction of inflammatory cytokines
    • Inhibition of neutrophil activation 1
  • In clinical studies, rebamipide has shown significant improvement in symptom scores and gastric inflammation in patients with gastric ulcers 1

Comparison with Other Treatments

  • Rebamipide (100 mg three times daily) has shown comparable efficacy to misoprostol (200 μg three times daily) in preventing NSAID-induced gastropathy 4
  • The occurrence rate of gastric ulcers after 12 weeks was similar between rebamipide and misoprostol groups (20.3% vs 21.9%) 4
  • However, rebamipide demonstrated fewer gastrointestinal side effects compared to misoprostol, with a significantly lower withdrawal rate (10.3% vs 18.6%) 4

Use in Combination Therapy

  • Rebamipide can be used in combination with proton pump inhibitors (PPIs) for enhanced ulcer healing 5
  • When combined with omeprazole, rebamipide has been shown to improve the quality of ulcer healing and reduce ulcer recurrence rates 5
  • The combination of omeprazole and rebamipide was found to be almost as effective as omeprazole plus amoxicillin in reducing ulcer recurrence 5

Safety Profile

  • Rebamipide is generally well-tolerated with few adverse effects 1
  • The drug has minimal systemic absorption, with mean serum concentrations remaining below 0.37 μg/ml 2
  • This low systemic distribution contributes to its favorable safety profile 2

Rebamipide represents an effective option for treating gastritis and gastric ulcers, with particular benefits for patients with NSAID-induced gastropathy due to its mucosal protective properties and favorable side effect profile.

References

1
Research

Effect of rebamipide on gastric ulcer healing caused by Helicobacter pylori and/or NSAIDs or non NSAIDs-non H. pylori.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009

Related Questions

What is the recommended dosage of Rebamipide (Rebamipide) for an adult patient with gastrointestinal issues, such as gastritis or gastric ulcers?
What are the recommended adult dose, administration instructions, treatment duration, side effects, contraindications, and alternative therapies for Rebamipide tablets?
What is the safe duration of rebamipide therapy for NSA‑induced gastropathy in an otherwise healthy adult?
What is the recommended treatment regimen for an adult patient with a diagnosed gastric or duodenal ulcer using Rebamipide?
In an adult patient requiring chronic non‑steroidal anti‑inflammatory drug therapy and at risk for NSAID‑induced gastropathy (e.g., older age, prior ulcer disease, high‑dose or multiple NSAIDs), what is the role of rebamipide for prevention or treatment, including recommended dosing and comparison to proton‑pump inhibitors?
What are the criteria for a bullectomy in patients with Chronic Obstructive Pulmonary Disease (COPD) based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines?
Can lichen sclerosus scarring be healed with topical corticosteroids (steroids)?
What is the management of melena in patients with Chronic Kidney Disease (CKD) on hemodialysis?
What are the symptoms of a thyroxine (T4) overdose?
What is the usage and dosage of dexmedetomidine (alpha-2 adrenergic agonist) for sedation in critically ill patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question